Walden Biosciences

Walden Biosciences is a Cambridge, Massachusetts clinical-stage biotech building first-in-class, disease-modifying medicines that target the kidney directly instead of just delaying the slide toward dialysis. Founded in 2020 on the podocyte and suPAR research of renal scientist Jochen Reiser and colleagues, Walden pairs an antibody program (WAL0921, against soluble urokinase plasminogen activator receptor) with a small-molecule program (WAL0623, a dynamin stabilizer) to protect and restore the kidney's filtration cells. Backed by ARCH Venture Partners, UCB Ventures, Mass General Brigham Ventures and ATEM Capital, the company is advancing WAL0921 through a Phase 2 basket study across common and rare glomerular kidney diseases.